patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_313918 | REC_0004301 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 17.6 | 56 | male | 1 | 4 | 5.8 | 0 | alectinib 600 mg BID | 10.3 | true | MSS | 2026-03-15T05:35:57.909669+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_815350 | REC_0004302 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 13.4 | 54 | female | 0 | 18 | 5.8 | 5 | osimertinib 80 mg daily | 12.1 | true | MSS | 2026-03-15T05:35:57.909904+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_758830 | REC_0004303 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 10 | 50 | male | 0 | 24 | 6.3 | 1 | alectinib 600 mg BID | 18.9 | true | MSI-H | 2026-03-15T05:35:57.910140+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_297417 | REC_0004304 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 16.7 | 72 | female | 2 | 11 | 6.2 | 5 | alectinib 600 mg BID | 9.7 | true | MSI-H | 2026-03-15T05:35:57.910442+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_459861 | REC_0004305 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 20 | 2.9 | 59 | male | 1 | 6 | 6.4 | 2 | pembrolizumab 200 mg q3w | 19.1 | false | MSS | 2026-03-15T05:35:57.910679+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_226431 | REC_0004306 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 24 | 13.7 | 63 | male | 0 | 15 | 3.9 | 0 | sotorasib 960 mg daily | 49.7 | false | MSI-H | 2026-03-15T05:35:57.910917+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_995514 | REC_0004307 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 12.4 | 74 | male | 2 | 20 | 6.7 | 5 | osimertinib 80 mg daily | 14.9 | true | MSS | 2026-03-15T05:35:57.911153+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_577555 | REC_0004308 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 15.6 | 72 | female | 3 | 17 | 5.2 | 5 | entrectinib 600 mg daily | 16.6 | true | MSS | 2026-03-15T05:35:57.911386+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_790697 | REC_0004309 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 16 | 63 | male | 1 | 20 | 5.7 | 4 | entrectinib 600 mg daily | 8.3 | false | MSI-H | 2026-03-15T05:35:57.911622+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_904029 | REC_0004310 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 10.1 | 68 | female | 0 | 10 | 4.5 | 7 | alectinib 600 mg BID | 11.1 | false | MSS | 2026-03-15T05:35:57.911851+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_476299 | REC_0004311 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 5.9 | 68 | female | 0 | 39 | 7.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 7.7 | false | MSS | 2026-03-15T05:35:57.912122+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_296528 | REC_0004312 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 4.7 | 78 | female | 2 | 14 | 4.7 | 3 | sotorasib 960 mg daily | 4.8 | false | MSS | 2026-03-15T05:35:57.912356+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_462309 | REC_0004313 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 9 | 77 | female | 1 | 7 | 6.2 | 6 | sotorasib 960 mg daily | 13.7 | false | MSS | 2026-03-15T05:35:57.912588+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_706160 | REC_0004314 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 13.8 | 77 | female | 1 | 9 | 6.1 | 6 | osimertinib 80 mg daily | 11.6 | false | MSI-H | 2026-03-15T05:35:57.912818+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_825076 | REC_0004315 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 4.9 | 55 | male | 0 | 71 | 7.9 | 5 | carboplatin + paclitaxel + pembrolizumab | 4 | true | MSS | 2026-03-15T05:35:57.913051+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_477345 | REC_0004316 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 14.3 | 73 | female | 1 | 16 | 5.1 | 2 | sotorasib 960 mg daily | 19.5 | true | MSS | 2026-03-15T05:35:57.913285+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_152001 | REC_0004317 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 4.7 | 90 | female | 1 | 7 | 7.7 | 2 | sotorasib 960 mg daily | 15 | true | MSS | 2026-03-15T05:35:57.913567+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_645923 | REC_0004318 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 9.1 | 66 | female | 0 | 37 | 6 | 4 | carboplatin + paclitaxel + pembrolizumab | 15.3 | true | MSS | 2026-03-15T05:35:57.913799+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_305655 | REC_0004319 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 5.2 | 68 | female | 1 | 15 | 7.3 | 1 | alectinib 600 mg BID | 12.8 | true | MSS | 2026-03-15T05:35:57.914029+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_706435 | REC_0004320 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 12 | 75 | female | 2 | 11 | 5.6 | 1 | sotorasib 960 mg daily | 14.3 | false | MSI-H | 2026-03-15T05:35:57.914262+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_566386 | REC_0004321 | Non-small cell lung cancer | Adenocarcinoma | III | None (PD-L1 high) | 27 | 14.8 | 59 | male | 1 | 14 | 5.7 | 0 | pembrolizumab 200 mg q3w | 31.9 | false | MSI-H | 2026-03-15T05:35:57.914500+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_445583 | REC_0004322 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 9.9 | 65 | female | 0 | 14 | 8.2 | 8 | osimertinib 80 mg daily | 10 | false | MSS | 2026-03-15T05:35:57.914730+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_932971 | REC_0004323 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 16.4 | 70 | female | 2 | 20 | 6.9 | 9 | osimertinib 80 mg daily | 11.8 | true | MSI-H | 2026-03-15T05:35:57.914960+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_893075 | REC_0004324 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 23 | 7.6 | 58 | male | 0 | 26 | 6.4 | 8 | pembrolizumab 200 mg q3w | 8.7 | true | MSS | 2026-03-15T05:35:57.915192+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_978421 | REC_0004325 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 10.1 | 77 | female | 2 | 11 | 6.6 | 6 | osimertinib 80 mg daily | 14.9 | false | MSI-H | 2026-03-15T05:35:57.915422+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_908702 | REC_0004326 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 13.9 | 74 | female | 2 | 10 | 6.3 | 7 | entrectinib 600 mg daily | 7.1 | false | MSS | 2026-03-15T05:35:57.915655+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_928901 | REC_0004327 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 15 | 8.2 | 61 | female | 1 | 54 | 6.1 | 8 | pembrolizumab 200 mg q3w | 7.3 | false | MSS | 2026-03-15T05:35:57.915887+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_127638 | REC_0004328 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 17.5 | 70 | male | 1 | 12 | 6.4 | 7 | osimertinib 80 mg daily | 15.2 | true | MSS | 2026-03-15T05:35:57.916226+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_243604 | REC_0004329 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 8.7 | 64 | female | 1 | 17 | 5.4 | 5 | alectinib 600 mg BID | 15.8 | false | MSS | 2026-03-15T05:35:57.916480+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_283695 | REC_0004330 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 14.3 | 67 | female | 0 | 16 | 3.5 | 5 | alectinib 600 mg BID | 17.4 | false | MSS | 2026-03-15T05:35:57.916777+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_173577 | REC_0004331 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 27 | 17.2 | 57 | male | 1 | 12 | 3.9 | 0 | osimertinib 80 mg daily | 39.7 | false | MSS | 2026-03-15T05:35:57.917021+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_256853 | REC_0004332 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 14.5 | 55 | female | 1 | 13 | 5.7 | 4 | osimertinib 80 mg daily | 14.1 | false | MSI-H | 2026-03-15T05:35:57.917257+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_879338 | REC_0004333 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 13.4 | 81 | female | 2 | 24 | 5.1 | 8 | osimertinib 80 mg daily | 4 | true | MSS | 2026-03-15T05:35:57.917489+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_406284 | REC_0004334 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 19 | 6.5 | 68 | female | 1 | 54 | 3.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 17.3 | false | MSS | 2026-03-15T05:35:57.917716+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_516742 | REC_0004335 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 30 | 8.9 | 73 | female | 2 | 20 | 6 | 2 | entrectinib 600 mg daily | 13.6 | true | MSS | 2026-03-15T05:35:57.917949+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_544996 | REC_0004336 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 14.1 | 72 | female | 2 | 20 | 6.4 | 1 | osimertinib 80 mg daily | 21.2 | false | MSS | 2026-03-15T05:35:57.918182+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_158618 | REC_0004337 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 5.4 | 68 | female | 0 | 101 | 2.2 | 1 | carboplatin + paclitaxel + pembrolizumab | 19.3 | false | MSS | 2026-03-15T05:35:57.918410+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_298377 | REC_0004338 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 10.7 | 69 | female | 1 | 12 | 4.4 | 4 | entrectinib 600 mg daily | 14.9 | true | MSI-H | 2026-03-15T05:35:57.918644+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_300174 | REC_0004339 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 18 | 12 | 58 | male | 0 | 17 | 7 | 1 | osimertinib 80 mg daily | 18 | false | MSS | 2026-03-15T05:35:57.918882+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_219845 | REC_0004340 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 13.7 | 63 | male | 1 | 16 | 5.4 | 7 | alectinib 600 mg BID | 6.9 | false | MSS | 2026-03-15T05:35:57.919115+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_421957 | REC_0004341 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 9.4 | 76 | female | 1 | 8 | 3.1 | 6 | osimertinib 80 mg daily | 15.9 | false | MSS | 2026-03-15T05:35:57.919348+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_924783 | REC_0004342 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 11.3 | 60 | male | 0 | 19 | 4.9 | 2 | entrectinib 600 mg daily | 16.6 | true | MSS | 2026-03-15T05:35:57.919590+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_661665 | REC_0004343 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 24 | 6.5 | 64 | female | 1 | 39 | 6.5 | 1 | pembrolizumab 200 mg q3w | 27.7 | true | MSS | 2026-03-15T05:35:57.919897+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_610434 | REC_0004344 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 6.8 | 77 | male | 2 | 62 | 4.3 | 4 | carboplatin + paclitaxel + pembrolizumab | 13.8 | true | MSS | 2026-03-15T05:35:57.920228+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_525726 | REC_0004345 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 18 | 10.8 | 67 | female | 1 | 14 | 4.9 | 2 | sotorasib 960 mg daily | 20.2 | false | MSI-H | 2026-03-15T05:35:57.920488+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_215812 | REC_0004346 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 18.1 | 67 | male | 0 | 14 | 4.6 | 9 | osimertinib 80 mg daily | 5.8 | true | MSS | 2026-03-15T05:35:57.920758+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_826881 | REC_0004347 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 1.5 | 58 | male | 0 | 36 | 6.4 | 2 | carboplatin + paclitaxel + pembrolizumab | 13.9 | true | MSS | 2026-03-15T05:35:57.921005+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_472552 | REC_0004348 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 14.5 | 67 | male | 0 | 21 | 4.1 | 2 | osimertinib 80 mg daily | 39 | true | MSS | 2026-03-15T05:35:57.921247+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_437798 | REC_0004349 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 25 | 5.3 | 62 | male | 0 | 54 | 8.2 | 0 | carboplatin + paclitaxel + pembrolizumab | 45.1 | true | MSS | 2026-03-15T05:35:57.921487+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_308263 | REC_0004350 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 13.9 | 55 | male | 1 | 17 | 8.3 | 5 | entrectinib 600 mg daily | 12 | true | MSS | 2026-03-15T05:35:57.921742+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_644822 | REC_0004351 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 4.4 | 87 | female | 1 | 28 | 3.8 | 5 | carboplatin + paclitaxel + pembrolizumab | 10.3 | false | MSS | 2026-03-15T05:35:57.921994+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_722405 | REC_0004352 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 3.4 | 57 | male | 1 | 13 | 5.3 | 1 | osimertinib 80 mg daily | 11.9 | false | MSS | 2026-03-15T05:35:57.922244+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_398568 | REC_0004353 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 8.8 | 76 | female | 1 | 17 | 5.8 | 5 | sotorasib 960 mg daily | 10.7 | true | MSS | 2026-03-15T05:35:57.922483+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_409796 | REC_0004354 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 15 | 12.7 | 57 | female | 1 | 11 | 6.2 | 4 | osimertinib 80 mg daily | 9.2 | false | MSI-H | 2026-03-15T05:35:57.922723+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_857021 | REC_0004355 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 11.7 | 63 | male | 1 | 6 | 3.8 | 7 | osimertinib 80 mg daily | 10.6 | true | MSI-H | 2026-03-15T05:35:57.922963+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_702007 | REC_0004356 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 14.3 | 75 | female | 2 | 11 | 5.5 | 7 | osimertinib 80 mg daily | 10.1 | false | MSS | 2026-03-15T05:35:57.923326+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_307955 | REC_0004357 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 32 | 16.5 | 78 | female | 1 | 30 | 5.7 | 6 | osimertinib 80 mg daily | 12.8 | false | MSS | 2026-03-15T05:35:57.923573+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_350842 | REC_0004358 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 13.4 | 64 | female | 0 | 20 | 3.4 | 5 | alectinib 600 mg BID | 9.9 | true | MSI-H | 2026-03-15T05:35:57.923813+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_624673 | REC_0004359 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 8.9 | 79 | female | 2 | 43 | 4.6 | 3 | carboplatin + paclitaxel + pembrolizumab | 12.6 | true | MSS | 2026-03-15T05:35:57.924043+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_625347 | REC_0004360 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 19 | 12.3 | 53 | male | 0 | 18 | 5.4 | 1 | osimertinib 80 mg daily | 18.5 | false | MSS | 2026-03-15T05:35:57.924343+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_217813 | REC_0004361 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 31 | 8.7 | 61 | male | 0 | 10 | 4.8 | 1 | pembrolizumab 200 mg q3w | 15.8 | true | MSS | 2026-03-15T05:35:57.924583+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_772363 | REC_0004362 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 34 | 6.5 | 77 | female | 2 | 14 | 5.6 | 0 | entrectinib 600 mg daily | 56.5 | false | MSS | 2026-03-15T05:35:57.924817+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_400268 | REC_0004363 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 6.1 | 68 | female | 1 | 12 | 7.3 | 6 | sotorasib 960 mg daily | 9 | true | MSS | 2026-03-15T05:35:57.925046+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_754506 | REC_0004364 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 22 | 16.9 | 72 | male | 2 | 19 | 5.5 | 7 | pembrolizumab 200 mg q3w | 11.4 | false | MSI-H | 2026-03-15T05:35:57.925281+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_264122 | REC_0004365 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 7.4 | 77 | female | 2 | 33 | 5.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 6 | false | MSS | 2026-03-15T05:35:57.925516+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_256195 | REC_0004366 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 21 | 7.4 | 66 | female | 1 | 27 | 4.4 | 4 | pembrolizumab 200 mg q3w | 5.4 | false | MSS | 2026-03-15T05:35:57.925748+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_264869 | REC_0004367 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 11.3 | 68 | female | 0 | 12 | 8 | 7 | osimertinib 80 mg daily | 7.7 | true | MSS | 2026-03-15T05:35:57.925980+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_683572 | REC_0004368 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 5.8 | 65 | male | 1 | 14 | 3.7 | 1 | osimertinib 80 mg daily | 21.2 | false | MSS | 2026-03-15T05:35:57.926208+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_943892 | REC_0004369 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 10.3 | 70 | female | 2 | 82 | 5.8 | 1 | carboplatin + paclitaxel + pembrolizumab | 15.8 | true | MSS | 2026-03-15T05:35:57.926517+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_589933 | REC_0004370 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 13.3 | 63 | male | 0 | 11 | 6 | 7 | sotorasib 960 mg daily | 5.8 | false | MSS | 2026-03-15T05:35:57.926757+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_788086 | REC_0004371 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 1.5 | 71 | female | 2 | 63 | 6.8 | 1 | carboplatin + paclitaxel + pembrolizumab | 17.8 | false | MSS | 2026-03-15T05:35:57.926986+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_138884 | REC_0004372 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 32 | 13.6 | 73 | female | 1 | 17 | 7.2 | 2 | osimertinib 80 mg daily | 21.9 | false | MSI-H | 2026-03-15T05:35:57.927224+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_680350 | REC_0004373 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 12.1 | 85 | female | 1 | 19 | 7.4 | 2 | osimertinib 80 mg daily | 19.9 | false | MSI-H | 2026-03-15T05:35:57.927455+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_890293 | REC_0004374 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 24.5 | 62 | female | 1 | 8 | 6.5 | 3 | sotorasib 960 mg daily | 13.4 | true | MSS | 2026-03-15T05:35:57.927691+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_886965 | REC_0004375 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 13.1 | 71 | female | 2 | 5 | 5.4 | 4 | osimertinib 80 mg daily | 9.6 | true | MSI-H | 2026-03-15T05:35:57.927929+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_325758 | REC_0004376 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 32 | 14.2 | 60 | male | 1 | 29 | 7.2 | 1 | entrectinib 600 mg daily | 12.7 | false | MSI-H | 2026-03-15T05:35:57.928222+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_834215 | REC_0004377 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 13 | 14 | 79 | male | 1 | 12 | 6.2 | 6 | osimertinib 80 mg daily | 4 | false | MSI-H | 2026-03-15T05:35:57.928475+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_304441 | REC_0004378 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 18.4 | 61 | male | 0 | 5 | 4.6 | 9 | alectinib 600 mg BID | 14.5 | false | MSI-H | 2026-03-15T05:35:57.928723+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_395613 | REC_0004379 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 17 | 12.7 | 80 | female | 1 | 10 | 5.5 | 2 | pembrolizumab 200 mg q3w | 10.2 | true | MSI-H | 2026-03-15T05:35:57.928957+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_813609 | REC_0004380 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 32 | 13.2 | 68 | male | 1 | 15 | 6.9 | 5 | pembrolizumab 200 mg q3w | 6.9 | false | MSS | 2026-03-15T05:35:57.929193+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_311756 | REC_0004381 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 4.8 | 74 | female | 1 | 63 | 6.8 | 5 | carboplatin + paclitaxel + pembrolizumab | 15.2 | false | MSS | 2026-03-15T05:35:57.929422+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_862240 | REC_0004382 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 27 | 14 | 67 | female | 1 | 10 | 4.3 | 1 | pembrolizumab 200 mg q3w | 18.2 | true | MSS | 2026-03-15T05:35:57.929717+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_806482 | REC_0004383 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 12.6 | 60 | female | 1 | 9 | 5.6 | 7 | osimertinib 80 mg daily | 10.1 | false | MSI-H | 2026-03-15T05:35:57.929959+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_557193 | REC_0004384 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 15.9 | 73 | female | 3 | 9 | 6.1 | 6 | sotorasib 960 mg daily | 8.3 | true | MSI-H | 2026-03-15T05:35:57.930191+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_189201 | REC_0004385 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 5.3 | 62 | female | 0 | 6 | 6.3 | 4 | osimertinib 80 mg daily | 14.4 | false | MSS | 2026-03-15T05:35:57.930424+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_817455 | REC_0004386 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 6.6 | 66 | male | 0 | 15 | 5.6 | 4 | sotorasib 960 mg daily | 10.5 | false | MSS | 2026-03-15T05:35:57.930654+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_326160 | REC_0004387 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 19 | 5.3 | 62 | female | 1 | 14 | 5.5 | 8 | pembrolizumab 200 mg q3w | 14.2 | false | MSS | 2026-03-15T05:35:57.930886+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_725479 | REC_0004388 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 28 | 11.7 | 66 | female | 0 | 14 | 4.9 | 4 | pembrolizumab 200 mg q3w | 14.1 | true | MSS | 2026-03-15T05:35:57.931125+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_257283 | REC_0004389 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 3.9 | 55 | male | 1 | 11 | 4.1 | 5 | carboplatin + paclitaxel + pembrolizumab | 12.2 | true | MSS | 2026-03-15T05:35:57.931357+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_798462 | REC_0004390 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 19.8 | 73 | male | 2 | 23 | 6.6 | 8 | alectinib 600 mg BID | 11.6 | true | MSI-H | 2026-03-15T05:35:57.931591+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_343677 | REC_0004391 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 14.1 | 77 | female | 1 | 14 | 4.7 | 2 | alectinib 600 mg BID | 7.5 | true | MSS | 2026-03-15T05:35:57.931824+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_128990 | REC_0004392 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 8.3 | 68 | female | 1 | 4 | 7.8 | 5 | entrectinib 600 mg daily | 10.9 | false | MSS | 2026-03-15T05:35:57.932050+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_791076 | REC_0004393 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 11.3 | 50 | female | 0 | 18 | 5.3 | 2 | sotorasib 960 mg daily | 22.6 | true | MSS | 2026-03-15T05:35:57.932338+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_278087 | REC_0004394 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 5.8 | 63 | male | 0 | 14 | 6.2 | 9 | osimertinib 80 mg daily | 9.3 | true | MSS | 2026-03-15T05:35:57.932576+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_499828 | REC_0004395 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 22 | 10.3 | 69 | female | 0 | 16 | 5.4 | 1 | pembrolizumab 200 mg q3w | 25.4 | true | MSS | 2026-03-15T05:35:57.932864+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_415358 | REC_0004396 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 11.9 | 73 | female | 0 | 16 | 7 | 6 | entrectinib 600 mg daily | 11.2 | false | MSI-H | 2026-03-15T05:35:57.933100+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_792812 | REC_0004397 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 17 | 11 | 74 | male | 1 | 22 | 4.5 | 2 | osimertinib 80 mg daily | 14.3 | false | MSS | 2026-03-15T05:35:57.933337+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_669353 | REC_0004398 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 6.7 | 60 | male | 0 | 38 | 4.2 | 2 | carboplatin + paclitaxel + pembrolizumab | 29.3 | true | MSS | 2026-03-15T05:35:57.933570+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_322340 | REC_0004399 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 11.4 | 64 | male | 0 | 2 | 7.2 | 3 | entrectinib 600 mg daily | 23.1 | true | MSS | 2026-03-15T05:35:57.933808+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_304147 | REC_0004400 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 5 | 78 | male | 2 | 45 | 5.7 | 5 | pembrolizumab 200 mg q3w | 4 | true | MSS | 2026-03-15T05:35:57.934040+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.